Thank you very much, Mr. Chair. I apologize for being a little late. I was doing a speech in the House. I know Ms. Sidhu was over there as well, so there may be a few different faces before us.
I want to go to where you left off with Mr. Kmiec. When you talked about patient groups that receive funding from pharmaceutical companies, we received a lot of patient groups writing in about PMPRB changes. I'm just wondering what threshold we are supposed to consider on support for our patient groups. It's a difficult one here.